FEDERAL COURT OF AUSTRALIA
Novartis AG v Arrow Pharmaceuticals Pty Ltd (No 2) [2020] FCA 1475
File number: NSD 859 of 2019 Judgment of: BURLEY J Date of judgment: 12 October 2020 Date of publication of reasons: 13 October 2020 Catchwords: PATENTS – appeal under s 60(4) of the Patents Act 1990 (Cth) – where opponent has filed submitting notice and Commissioner of Patents is not taking active part in proceedings – where there is no evidence to support grounds of opposition – appeal allowed – opposition dismissed – patent allowed to proceed to grant Legislation: Patents Act 1990 (Cth) ss 18(1)(b)(ii), 59, 60 and 105(1A) Cases cited: Arrow Pharmaceuticals Pty Ltd v Novartis AG [2019] APO 22
Cadbury Schweppes Plc v Effem Foods Pty Ltd [2006] FCA 1267; (2006) 69 IPR 584
Daiichi Sankyo Company, Limited v Alethia Biotherapeutics Inc. [2016] FCA 1540
European Community v Commissioner of Patents [2006] FCA 706; (2006) 68 IPR 539
Division: General Division Registry: New South Wales National Practice Area: Intellectual Property Sub-area: Patents and associated Statutes Number of paragraphs: 8 Date of hearing: 12 October 2020 Counsel for the Appellant: Mr C. Burgess Solicitor for the Appellant: Clayton Utz Counsel for the Respondent: The Respondent filed a submitting notice, save as to costs ORDERS
NSD 859 of 2019 BETWEEN: NOVARTIS AG
Appellant
AND: ARROW PHARMACEUTICALS PTY LTD
Respondent
ORDER MADE BY:
BURLEY J
DATE OF ORDER:
12 OCTOBER 2020
THE COURT ORDERS THAT:
1.The appeal be allowed.
2.The decision of the delegate of the Commissioner made on 10 May 2019 concerning opposed Australian Patent Application No. 2013204752 ([2019] APO 22) be set aside.
3.Arrow Pharmaceuticals Pty Ltd's opposition to Australian Patent Application No. 2013204752, including as amended pursuant to order 1 of the orders made by Jagot J on 24 February 2020, be dismissed.
4.Australian Patent Application No. 2013204752, as amended pursuant to order 1 of the orders made by Jagot J on 24 February 2020, proceed to grant.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
REASONS FOR JUDGMENT
(Revised from transcript)BURLEY J:
The appellant, Novartis AG, is the applicant for Australian patent application No. 2013204752 which bears the title “Pharmaceutical compositions comprising an S1P modulator”. Broadly, the application relates to pharmaceutical compositions that comprise an S1P modulator, including methods of treating or preventing multiple sclerosis, and methods of protecting against neurodegenerative brain inflammation, that involve administering such compositions.
The patent application was examined and accepted by the Commissioner of Patents, and the respondent, Arrow Pharmaceuticals Pty Ltd subsequently filed a notice of opposition pursuant to s 59 of the Patents Act 1990 (Cth). On 10 May 2019 a delegate of the Commissioner upheld the opposition under s 60 of the Patents Act, on the basis that the claimed invention lacked an inventive step within s 18(1)(b)(ii): Arrow Pharmaceuticals Pty Ltd v Novartis AG [2019] APO…
Keep reading for free
Create a free CaseChat account to read Novartis AG v Arrow Pharmaceuticals Pty Ltd (No 2) and more:
- Read every judgment in full
- Ask AI and get answers linked to paragraphs
- See how each paragraph was cited in later cases
- Download judgments as PDF or Word
One click creates your free account or signs you in.
By continuing you agree to the Terms and Privacy Policy.
- Case
- [2020] FCA 1475
- Decision Date
CaseChat Overview and Summary
The court needed to determine whether the delegate's decision was legally sound, particularly considering the Commissioner was not actively participating in the proceedings due to the opponent filing a submitting notice. The legal issues centred around the application of section 60(4) of the Patents Act 1990 (Cth) and whether the delegate's decision was based on proper evidence. The court had to assess whether there was sufficient evidence to support the grounds of opposition and whether the Commissioner's delegate had the authority to make a decision without the Commissioner's active involvement.
The court concluded that the Commissioner's delegate did not have sufficient evidence to support the grounds of opposition. The reasoning was that the decision did not align with the legal standards required for such determinations, and the lack of active participation by the Commissioner further undermined the decision's validity. The court allowed the appeal, set aside the decision of the delegate, dismissed Arrow Pharmaceuticals Pty Ltd's opposition, and ordered the patent application to proceed to grant. This decision was made considering the statutory framework and the procedural fairness owed to the parties involved.
Orders
Orders of the court
1. The appeal be allowed.
2. The decision of the delegate of the Commissioner made on 10 May 2019 concerning opposed Australian Patent Application No. 2013204752 ([2019] APO 22) be set aside.
3. Arrow Pharmaceuticals Pty Ltd's opposition to Australian Patent Application No. 2013204752, including as amended pursuant to order 1 of the orders made by Jagot J on 24 February 2020, be dismissed.
4. Australian Patent Application No. 2013204752, as amended pursuant to order 1 of the orders made by Jagot J on 24 February 2020, proceed to grant.
Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.
Background
Background to the litigation
Full text does not contain this section.
Evidence
Evidence Before The Court
Full text does not contain this section.
Decision
Reasons for decision
Full text does not contain this section.
Ratio Decidendi
Legal Principle Established
Full text does not contain this section.